- Filed
- May 7, 2026 12:00 AM ET
- Period of report
- —
Restated figures. One or more values in this filing restate previously reported amounts.
On SEC.gov
Financials in this filing
| Metric | Period | Value |
|---|---|---|
| Shares Diluted | Q2 2026 · Mar 31, 2026 | 280.64M sh |
| Shares Diluted | Q2 2026 · Mar 31, 2026 | 284.63M sh |
| Shares Diluted | Q2 2026 · Mar 31, 2025 | 287.74M sh |
| Shares Diluted | Q2 2026 · Mar 31, 2025 | 289.19M sh |
| Shares Outstanding | Q2 2026 · Mar 31, 2026 | 275.54M sh |
| Stock Repurchased | Q2 2026 · Mar 31, 2026 | $2.25B |
| Stock Repurchased | Q2 2026 · Mar 31, 2025 | $750M |
| Capex | Q2 2026 · Mar 31, 2026 | $233M |
| Capex restated | Q2 2026 · Mar 31, 2025 | $219M |
| Long Term Debt | Q2 2026 · Mar 31, 2026 | $14.71B |
| Long Term Debt | Q2 2026 · Sep 30, 2025 | $17.62B |
| Short Term Debt | Q2 2026 · Mar 31, 2026 | $2.57B |
| Short Term Debt | Q2 2026 · Sep 30, 2025 | $1.56B |
| Cash And Equivalents | Q2 2026 · Mar 31, 2026 | $813M |
| Cash And Equivalents | Q2 2026 · Sep 30, 2025 | $567M |
| Stockholders Equity | Q2 2026 · Mar 31, 2026 | $24.13B |
| Stockholders Equity | Q2 2026 · Sep 30, 2025 | $25.39B |
| Current Liabilities | Q2 2026 · Mar 31, 2026 | $8.51B |
| Current Liabilities | Q2 2026 · Sep 30, 2025 | $8.31B |
| Current Assets | Q2 2026 · Mar 31, 2026 | $8.01B |
| Current Assets | Q2 2026 · Sep 30, 2025 | $9.26B |
| Total Assets | Q2 2026 · Mar 31, 2026 | $50.83B |
| Total Assets | Q2 2026 · Sep 30, 2025 | $55.33B |
| Eps Diluted | Q2 2026 · Mar 31, 2026 | −$1.11 |
| Eps Diluted | Q2 2026 · Mar 31, 2026 | $0.25 |
| Eps Diluted | Q2 2026 · Mar 31, 2025 | $1.07 |
| Eps Diluted | Q2 2026 · Mar 31, 2025 | $2.11 |
| Eps Basic | Q2 2026 · Mar 31, 2026 | −$1.11 |
| Eps Basic | Q2 2026 · Mar 31, 2026 | $0.25 |
| Eps Basic | Q2 2026 · Mar 31, 2025 | $1.07 |
| Eps Basic | Q2 2026 · Mar 31, 2025 | $2.12 |
| Sga Expense | Q2 2026 · Mar 31, 2026 | $1.21B |
| Sga Expense | Q2 2026 · Mar 31, 2026 | $2.44B |
| Sga Expense restated | Q2 2026 · Mar 31, 2025 | $1.12B |
| Sga Expense restated | Q2 2026 · Mar 31, 2025 | $2.27B |
| Rd Expense | Q2 2026 · Mar 31, 2026 | $249M |
| Rd Expense | Q2 2026 · Mar 31, 2026 | $484M |
| Rd Expense restated | Q2 2026 · Mar 31, 2025 | $232M |
| Rd Expense restated | Q2 2026 · Mar 31, 2025 | $476M |
| Net Income | Q2 2026 · Mar 31, 2026 | −$311M |
| Net Income | Q2 2026 · Mar 31, 2026 | $72M |
| Net Income | Q2 2026 · Mar 31, 2025 | $308M |
| Net Income | Q2 2026 · Mar 31, 2025 | $611M |
| Operating Income | Q2 2026 · Mar 31, 2026 | $93M |
| Operating Income | Q2 2026 · Mar 31, 2026 | $562M |
| Operating Income restated | Q2 2026 · Mar 31, 2025 | $383M |
| Operating Income restated | Q2 2026 · Mar 31, 2025 | $665M |
| Cost Of Revenue | Q2 2026 · Mar 31, 2026 | $2.56B |
| Cost Of Revenue | Q2 2026 · Mar 31, 2026 | $4.99B |
| Cost Of Revenue restated | Q2 2026 · Mar 31, 2025 | $2.62B |
| Cost Of Revenue restated | Q2 2026 · Mar 31, 2025 | $5.16B |
| Revenue | Q2 2026 · Mar 31, 2026 | $4.71B |
| Revenue | Q2 2026 · Mar 31, 2026 | $9.2B |
| Revenue restated | Q2 2026 · Mar 31, 2025 | $4.48B |
| Revenue restated | Q2 2026 · Mar 31, 2025 | $8.81B |